Review of current and pipeline drugs for treatment of melanoma
18 February 2024This review provides insights into current melanoma treatments and recent therapeutic advances.
Smoking may be considered a risk factor for stage I and II melanoma disease progression
18 February 2024Findings of this recent study suggest that patients with clinical stage I and II melanoma who smoked had a significantly increased risk of death due to melanoma. Smoking status should be assessed at time of melanoma diagnosis and may be considered a risk factor for disease progression.
Opportunities for improving skin cancer prevention activities in primary care
18 February 2024According to this recent study, there are potential opportunities for improving skin cancer prevention activities in primary care. Ensuring ease of programme delivery, integration with early detection and availability of resources such as risk assessment tools are enablers to encourage and increase uptake of primary prevention behaviours in primary care, for both practitioners and patients.
Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy
18 February 2024This study aims to evaluate the impact of adjuvant anti-PD1 therapy on the health-related quality of life (HRQOL) of patients with resected stage III/IV melanoma. It concludes that a significant proportion of patients with resected stage III/IV melanoma who received adjuvant anti-PD1 experienced clinically significant declines in role, social and emotional functioning at 12 months compared to baseline. It highlights the HRQOL issues that may arise during adjuvant anti-PD1 therapy which may require supportive care intervention.
MIA calculator to predict recurrence-free and overall survival for patients with stage II melanoma
18 February 2024According to this recent study, models developed by Melanoma Institute Australia (MIA) offer accurate and personalized estimates of both recurrence-free survival and overall survival in patients with stage II melanoma, even in the absence of pathological staging with sentinel node biopsy.
Combining dermatologists' knowledge with CNNs shows high performances for melanoma detection
16 February 2024According to this recent study, merging the knowledge of dermatologists with Convolutional Neural Networks (CNNs) showed high performances for melanoma detection, encouraging collaboration between computer science and medical fields.
Position statement of the EADV Artificial Intelligence (AI) Task Force on AI-assisted smartphone apps and web-based services for skin disease
28 January 2024This objective of this article is to offer insights and recommendations for the present and future deployment of AI-assisted smartphone apps and web-based services for skin diseases with emphasis on skin cancer detection. The article concludes that the utilisation of AI-assisted smartphone apps and web-based services in diagnosing and treating skin diseases has the potential to greatly benefit patients in their dermatology journeys. By prioritising innovation, fostering collaboration and implementing effective regulations, we can ensure the successful integration of these apps into clinical practice.
Association between statin use and reduced disease recurrence in resected cutaneous melanoma
18 January 2024This recent study supports the possibility that an association exists between statin use and reduced disease recurrence in resected cutaneous melanoma.
Photoacoustic imaging could aid in early diagnosis and classification of cutaneous melanoma
18 January 2024According to this recent study, photoacoustic imaging is a promising technique for assessing the status of the skin without a surgical procedure. The capability of the modality to image microvasculature, visualize tumor boundaries, detect metastases in lymph nodes, perform fast and label-free histology, and identify circulating tumor cells could aid in the early diagnosis and classification of cutaneous melanoma, including determination of metastatic status, and could be useful for monitoring treatment efficacy noninvasively.
Spatial imaging technologies are just beginning to transform our understanding of melanoma biology
17 January 2024Spatial imaging technologies are being increasingly used to study the melanoma tumor microenvironment. The goal of such studies is to understand the complex interplay between the stroma, melanoma cells, and immune cell-types as well as their association with treatment response. According to this recent study, spatial imaging technologies are just beginning to transform our understanding of melanoma biology, providing new avenues for biomarker discovery and therapeutic development, and holding great promise for advancing personalized medicine to improve patient outcomes in melanoma and other solid malignancies.